Ahmed A. Arif

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress et al. · The Lancet · 2019 · 612 citations · Full text

Medicine, Endocrinology, Nephrology +10

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 311 citations

Pharmacy, Pharmacology, Pharmacotherapy +6

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Thomas R. Pieber, Bruce W. Bode, Young Min Cho et al. · The Lancet Diabetes & Endocrinology · 2019 · 274 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +9

Patterns of alcohol drinking and its association with obesity: data from the third national health and nutrition examination survey, 1988–1994

Ahmed A. Arif, James E. Rohrer · BMC Public Health · 2005 · 229 citations · Full text

Public Health, Nutrition, Public Health Nutrition +7